Bio-Rad Laboratories, Inc. $BIO Shares Purchased by AYAL Capital Advisors Ltd

AYAL Capital Advisors Ltd lifted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 14.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,000 shares of the medical research company’s stock after purchasing an additional 2,500 shares during the quarter. Bio-Rad Laboratories comprises about 2.1% of AYAL Capital Advisors Ltd’s portfolio, making the stock its 9th biggest position. AYAL Capital Advisors Ltd owned approximately 0.07% of Bio-Rad Laboratories worth $6,060,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in BIO. Danske Bank A S acquired a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth $30,000. Geneos Wealth Management Inc. raised its stake in Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Bio-Rad Laboratories in the 4th quarter worth $47,000. Farther Finance Advisors LLC raised its stake in Bio-Rad Laboratories by 76.9% in the 4th quarter. Farther Finance Advisors LLC now owns 184 shares of the medical research company’s stock worth $56,000 after acquiring an additional 80 shares during the last quarter. Finally, Itau Unibanco Holding S.A. raised its stake in Bio-Rad Laboratories by 57.6% in the 4th quarter. Itau Unibanco Holding S.A. now owns 197 shares of the medical research company’s stock worth $60,000 after acquiring an additional 72 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on BIO. Citigroup lowered Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $375.00 to $300.00 in a research note on Tuesday, April 7th. Weiss Ratings lowered Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Wells Fargo & Company reduced their target price on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research note on Friday, May 1st. Finally, Royal Bank Of Canada began coverage on Bio-Rad Laboratories in a research note on Friday, May 15th. They issued an “outperform” rating and a $320.00 target price for the company. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bio-Rad Laboratories has an average rating of “Hold” and a consensus target price of $303.33.

Bio-Rad Laboratories Stock Performance

NYSE BIO opened at $284.77 on Thursday. The stock has a 50-day simple moving average of $284.41 and a two-hundred day simple moving average of $290.07. The firm has a market capitalization of $7.62 billion, a P/E ratio of 46.91 and a beta of 1.08. Bio-Rad Laboratories, Inc. has a fifty-two week low of $228.40 and a fifty-two week high of $343.12. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.37 and a current ratio of 3.21.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 earnings per share for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). The company had revenue of $592.10 million for the quarter, compared to analysts’ expectations of $589.91 million. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The business’s quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.54 EPS. On average, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 9.42 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.